[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586992":3},{"organization":4,"armGroups":7,"interventions":46,"overallOfficials":68,"centralContacts":72,"locations":77,"responsibleParty":307,"collaborators":309,"id":312,"slug":313,"hasResults":314,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":52,"eligibilityCriteria":318,"healthyVolunteers":314,"sex":319,"minAge":320,"maxAge":52,"enrollmentInfo":321,"targetDuration":52,"studyType":324,"phases":325,"briefSummary":328,"conditions":329,"keywords":338,"overallStatus":80,"whyStopped":52,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":353},{"fullName":5,"class":6},"Tango Therapeutics, Inc.","INDUSTRY",[8,15,20,24,28,33,38,42],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation 1A","EXPERIMENTAL","Escalating oral doses of TNG462 in combination with oral RMC-6236",[13,14],"Drug: TNG462","Drug: RMC-6236",{"label":16,"type":10,"description":17,"interventionNames":18},"Dose escalation 1B","Escalating oral doses of TNG462 in combination with oral RMC-9805",[13,19],"Drug: RMC-9805",{"label":21,"type":10,"description":22,"interventionNames":23},"Dose Expansion 2A","Expansion arm at the RDE(s) of oral TNG462 in combination with oral RMC-6236",[13,14],{"label":25,"type":10,"description":26,"interventionNames":27},"Dose Expansion 2B","Expansion arm at the RDE(s) of oral TNG462 in combination with oralRMC-9805",[13,19],{"label":29,"type":10,"description":30,"interventionNames":31},"Experimental: Dose Escalation 1C","Escalating doses of TNG462 in combination with mFOLFIRINOX",[13,32],"Drug: mFOLFIRINOX",{"label":34,"type":10,"description":35,"interventionNames":36},"Experimental: Dose Escalation 1D","Escalating doses of TNG462 in combination with gemcitabine\u002Fnab-paclitaxel",[13,37],"Drug: gemcitabine\u002Fnab-paclitaxel",{"label":39,"type":10,"description":40,"interventionNames":41},"Experimental: Dose Expansion 2C","Expansion arm at the RDE(s) of TNG462 in combination with mFOLFIRINOX",[13,32],{"label":43,"type":10,"description":44,"interventionNames":45},"Experimental: Dose Expansion 2D","Expansion arm at the RDE(s) of TNG462 in combination with gemcitabine\u002Fnab-paclitaxel",[13,37],[47,53,57,61,65],{"type":48,"name":49,"description":50,"armGroupLabels":51,"otherNames":52},"DRUG","TNG462","MTA cooperative PRMT5 inhibitor",[9,21,25,16,29,34,39,43],null,{"type":48,"name":54,"description":55,"armGroupLabels":56,"otherNames":52},"RMC-9805","RAS(ON) G12D selective covalent inhibitor",[25,16],{"type":48,"name":58,"description":59,"armGroupLabels":60,"otherNames":52},"RMC-6236","RAS(ON) multi-selective inhibitor",[9,21],{"type":48,"name":62,"description":63,"armGroupLabels":64,"otherNames":52},"mFOLFIRINOX","Chemotherapy",[29,39],{"type":48,"name":66,"description":63,"armGroupLabels":67,"otherNames":52},"gemcitabine\u002Fnab-paclitaxel",[34,43],[69],{"name":70,"affiliation":5,"role":71},"Maxim Pimpkin, MD, PhD","STUDY_DIRECTOR",[73],{"name":70,"role":74,"phone":75,"phoneExt":52,"email":76},"CONTACT","857-320-4899","clinicaltrials@tangotx.com",[78,96,109,122,135,148,161,174,187,196,209,222,234,243,256,269,281,294],{"facility":79,"status":80,"city":81,"state":82,"zip":83,"country":84,"countryCode":85,"cosmosGeoPoint":86,"geoPoint":91,"contacts":92},"Mayo Clinic Scottsdale","RECRUITING","Scottsdale","Arizona","85259-5452","United States","US",{"type":87,"coordinates":88},"Point",[89,90],-111.89903,33.50921,{"lat":90,"lon":89},[93],{"name":94,"role":95,"phone":52,"phoneExt":52,"email":52},"Mitesh Borad, MD","PRINCIPAL_INVESTIGATOR",{"facility":97,"status":80,"city":98,"state":99,"zip":100,"country":84,"countryCode":85,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"Sarah Cannon Research Institute Denver","Denver","Colorado","80218",{"type":87,"coordinates":102},[103,104],-104.9847,39.73915,{"lat":104,"lon":103},[107],{"name":108,"role":95,"phone":52,"phoneExt":52,"email":52},"Gerald Falchook, MD, MS",{"facility":110,"status":80,"city":111,"state":112,"zip":113,"country":84,"countryCode":85,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"Georgetown University Medical Center","Washington D.C.","District of Columbia","20007",{"type":87,"coordinates":115},[116,117],-77.03637,38.89511,{"lat":117,"lon":116},[120],{"name":121,"role":95,"phone":52,"phoneExt":52,"email":52},"Marcus Noel, MD",{"facility":123,"status":80,"city":124,"state":125,"zip":126,"country":84,"countryCode":85,"cosmosGeoPoint":127,"geoPoint":131,"contacts":132},"Mayo Clinic Jacksonville","Jacksonville","Florida","32224",{"type":87,"coordinates":128},[129,130],-81.65565,30.33218,{"lat":130,"lon":129},[133],{"name":134,"role":95,"phone":52,"phoneExt":52,"email":52},"Hani Babiker, MD",{"facility":136,"status":80,"city":137,"state":138,"zip":139,"country":84,"countryCode":85,"cosmosGeoPoint":140,"geoPoint":144,"contacts":145},"Northwestern Memorial Hospital","Chicago","Illinois","60611-2908",{"type":87,"coordinates":141},[142,143],-87.65005,41.85003,{"lat":143,"lon":142},[146],{"name":147,"role":95,"phone":52,"phoneExt":52,"email":52},"Chengwei Peng, MD",{"facility":149,"status":80,"city":150,"state":151,"zip":152,"country":84,"countryCode":85,"cosmosGeoPoint":153,"geoPoint":157,"contacts":158},"University of Indiana","Indianapolis","Indiana","46202",{"type":87,"coordinates":154},[155,156],-86.15804,39.76838,{"lat":156,"lon":155},[159],{"name":160,"role":95,"phone":52,"phoneExt":52,"email":52},"Anita Turk, MD",{"facility":162,"status":80,"city":163,"state":164,"zip":165,"country":84,"countryCode":85,"cosmosGeoPoint":166,"geoPoint":170,"contacts":171},"University of Iowa Health Care","Iowa City","Iowa","52242",{"type":87,"coordinates":167},[168,169],-91.53017,41.66113,{"lat":169,"lon":168},[172],{"name":173,"role":95,"phone":52,"phoneExt":52,"email":52},"Naomi Fei, MD, MS",{"facility":175,"status":80,"city":176,"state":177,"zip":178,"country":84,"countryCode":85,"cosmosGeoPoint":179,"geoPoint":183,"contacts":184},"Massachusetts General Hospital","Boston","Massachusetts","02114",{"type":87,"coordinates":180},[181,182],-71.05977,42.35843,{"lat":182,"lon":181},[185],{"name":186,"role":95,"phone":52,"phoneExt":52,"email":52},"Harshabad Singh, MD",{"facility":188,"status":80,"city":176,"state":177,"zip":189,"country":84,"countryCode":85,"cosmosGeoPoint":190,"geoPoint":192,"contacts":193},"Dana-Farber Cancer Institute","02115",{"type":87,"coordinates":191},[181,182],{"lat":182,"lon":181},[194],{"name":195,"role":95,"phone":52,"phoneExt":52,"email":52},"Kimberly Perez, MD",{"facility":197,"status":80,"city":198,"state":199,"zip":200,"country":84,"countryCode":85,"cosmosGeoPoint":201,"geoPoint":205,"contacts":206},"Mayo Clinic Cancer Center","Rochester","Minnesota","55905-0001",{"type":87,"coordinates":202},[203,204],-92.4699,44.02163,{"lat":204,"lon":203},[207],{"name":208,"role":95,"phone":52,"phoneExt":52,"email":52},"Kaushal Parikh, MD",{"facility":210,"status":80,"city":211,"state":212,"zip":213,"country":84,"countryCode":85,"cosmosGeoPoint":214,"geoPoint":218,"contacts":219},"Nebraska Cancer Specialists","Omaha","Nebraska","68124",{"type":87,"coordinates":215},[216,217],-95.94043,41.25626,{"lat":217,"lon":216},[220],{"name":221,"role":95,"phone":52,"phoneExt":52,"email":52},"Joel Michalski, MD, PhD",{"facility":223,"status":80,"city":224,"state":224,"zip":225,"country":84,"countryCode":85,"cosmosGeoPoint":226,"geoPoint":230,"contacts":231},"NYU Langone Health","New York","10016",{"type":87,"coordinates":227},[228,229],-74.00597,40.71427,{"lat":229,"lon":228},[232],{"name":233,"role":95,"phone":52,"phoneExt":52,"email":52},"Kristen Spencer, DO, MPH",{"facility":235,"status":80,"city":224,"state":224,"zip":236,"country":84,"countryCode":85,"cosmosGeoPoint":237,"geoPoint":239,"contacts":240},"Memorial Sloan Kettering Cancer Center","11065",{"type":87,"coordinates":238},[228,229],{"lat":229,"lon":228},[241],{"name":242,"role":95,"phone":52,"phoneExt":52,"email":52},"Eileen O'Reilly, MD",{"facility":244,"status":80,"city":245,"state":246,"zip":247,"country":84,"countryCode":85,"cosmosGeoPoint":248,"geoPoint":252,"contacts":253},"University of North Carolina at Chapel Hill","Chapel Hill","North Carolina","27599-7305",{"type":87,"coordinates":249},[250,251],-79.05584,35.9132,{"lat":251,"lon":250},[254],{"name":255,"role":95,"phone":52,"phoneExt":52,"email":52},"Shetal Patel, MD, PhD",{"facility":257,"status":80,"city":258,"state":259,"zip":260,"country":84,"countryCode":85,"cosmosGeoPoint":261,"geoPoint":265,"contacts":266},"University of Texas MD Anderson Cancer Center","Houston","Texas","77030",{"type":87,"coordinates":262},[263,264],-95.36327,29.76328,{"lat":264,"lon":263},[267],{"name":268,"role":95,"phone":52,"phoneExt":52,"email":52},"Jordi Rodon Ahnert, MD",{"facility":270,"status":80,"city":271,"state":259,"zip":272,"country":84,"countryCode":85,"cosmosGeoPoint":273,"geoPoint":277,"contacts":278},"NEXT Dallas","Irving","74039",{"type":87,"coordinates":274},[275,276],-96.94889,32.81402,{"lat":276,"lon":275},[279],{"name":280,"role":95,"phone":52,"phoneExt":52,"email":52},"Siraj Sen, MD",{"facility":282,"status":80,"city":283,"state":284,"zip":285,"country":84,"countryCode":85,"cosmosGeoPoint":286,"geoPoint":290,"contacts":291},"Huntsman Cancer Institute, University of Utah","Salt Lake City","Utah","84112",{"type":87,"coordinates":287},[288,289],-111.89105,40.76078,{"lat":289,"lon":288},[292],{"name":293,"role":95,"phone":52,"phoneExt":52,"email":52},"Vaia Florou, MD, MS",{"facility":295,"status":80,"city":296,"state":297,"zip":298,"country":84,"countryCode":85,"cosmosGeoPoint":299,"geoPoint":303,"contacts":304},"NEXT Oncology","Fairfax","Virginia","22031",{"type":87,"coordinates":300},[301,302],-77.30637,38.84622,{"lat":302,"lon":301},[305],{"name":306,"role":95,"phone":52,"phoneExt":52,"email":52},"Alexander Spira, MD, PhD",{"type":308,"investigatorFullName":52,"investigatorTitle":52,"investigatorAffiliation":52,"oldNameTitle":52,"oldOrganization":52},"SPONSOR",[310],{"name":311,"class":6},"Revolution Medicines, Inc.","100586992","phase-1-study-to-evaluate-the-safety-tolerability--efficacy-of-tng462-in-combination-in-pdac--nsclc-patients-100586992",false,"NCT06922591","Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients","A Phase 1\u002F2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic Cancer With MTAP Loss and Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation","Inclusion Criteria:\n\n1. Is ≥18 years of age at the time of signature of the main study ICF.\n2. Has an ECOG PS of 0 or 1.\n3. Has a tumor with loss of MTAP protein or bi-allelic deletion of the MTAP gene\n4. Arms A and B only: Has a tumor with a RAS mutation\n5. Pathologically documented metastatic PDAC or locally advanced, recurrent or metastatic NSCLC\n6. Has received prior standard therapy\n7. Arms A and B only: Must not have received prior RAS-targeted therapy\n8. Has evidence of measurable disease based on RECIST v1.1.\n9. Adequate organ function\n10. Must be able to swallow tablets.\n11. Negative pregnancy test at screening\n12. Written informed consent must be obtained according to local guidelines\n\nExclusion Criteria:\n\n1. Has received prior treatment with a PRMT5 inhibitor, or MAT2A inhibitor\n2. Arms A and B only: Prior enrollment in any phase 3 clinical trial of RMC-6236 or RMC-9805\n3. Known allergy, hypersensitivity or intolerance to TNG462 (all arms), RMC-6236 Arm A), RMC-9805 (Arm B), mFOLFIRINOX (Arm C), gemcitabine\u002Fnab-paclitaxel (Arm D) or their excipients\n4. Has uncontrolled intercurrent illness that will limit compliance with the study requirements.\n5. Has an active infection requiring systemic therapy.\n6. Is currently participating in or has planned concurrent participation in a study of another investigational agent or device.\n7. Has impairment of GI function or disease that may significantly alter the absorption of the oral medications\n8. Has known or suspected active or untreated CNS metastases associated with progressive neurological symptoms\n9. Has current active liver disease from any cause\n10. Is known to be HIV positive, unless all the following criteria are met:\n\n    1. CD4+ count ≥300\u002FµL.\n    2. Undetectable viral load.\n    3. Receiving highly active antiretroviral therapy\n11. Has clinically relevant cardiovascular disease\n12. History of or presence of active interstitial lung disease\n13. Is a female patient who is pregnant or lactating\n14. Is unwilling or unable to comply with the scheduled visits, study treatment administration plan, laboratory tests or other study procedures and study restrictions.\n15. Has a prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion may affect the safety of the patient or impair the ability to assess study results","ALL","18 Years",{"count":322,"type":323},183,"ESTIMATED","INTERVENTIONAL",[326,327],"PHASE1","PHASE2","TNG462-C102 is a Phase 1\u002F2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine\u002Fnab-paclitaxel. The study comprises a dose escalation phase and a dose expansion phase.",[330,331,332,333,334,335,336,337],"PDAC","PDAC - Pancreatic Ductal Adenocarcinoma","NSCLC","RAS Mutation","MTAP Deletion","Lung Cancer","Pancreatic Cancer Metastatic","Thoracic Cancer",[339,340,341,54,58,342,343],"PRMT5 inhibitor","RAS G12D","Multi RAS","Thoracic","Targeted therapy","2026-05-12",{"date":346,"type":347},"2026-05-14","ACTUAL",{"date":349,"type":347},"2025-05-31",{"date":351,"type":323},"2027-12",{"name":5,"class":6},18]